8-Bromo-7-(2-butyn-1-yl)-3-methylxanthine CAS 666816-98-4

Description:

Nomen: 8-Bromo-7-(2-butyn-1-yl) -3-methylxanthine

CAS: 666816-98-4

Puritas: ≥99.0% (HPLC)

Aspectus: Alba ad Off-White pulveris

Intermedia pro Linagliptin (CAS: 668270-12-0) pro adultorum specie diabete mellito tractandis.

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Manufacturer Supple Linagliptin et intermedia:
Linagliptin CAS 668270-12-0
Linagliptin Parent Nucleus Intermedia CAS 853029-57-9
8-Bromo-3-Methylxanthine CAS 93703-24-3
8-Bromo-7-(2-butyn-1-yl) -3-methylxanthine CAS 666816-98-4
2-(Chloromethyl) -4-Methylquinazoline CAS 109113-72-6
(R) -3-(Boc-Amino) piperidine CAS 309956-78-3
(R)-(-)-3-Aminopiperidine dihydrochloride CAS 334618-23-4
1-Bromo-2-Butyne CAS 3355-28-0

Chemical Properties:

Nomen chemicum	8-Bromo-7-(2-butyn-1-yl) -3-methylxanthine
Synonyma	8-bromo-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1H-purinum-2,6-dione;Linagliptin medium C
CAS Number	666816-98-4
CATTUS Number	RF-PI497
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C10H9BrN4O2
M. Pondus	297.11
Liquescens punctum	285℃
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba ad Off-White pulveris
Aquae (KF)	≤0.50%
Residere in Ignition	≤0.50%
Puritas / Analysis Methodo	≥99.0% (HPLC)
Max Single immunitas	≤0.50%
RELICTUM Solvents
Ethanol	≤5000ppm
DMF	≤3000ppm
Test Standard	Enterprise Standard
Consuetudinem	Intermedia pro Linagliptin (CAS: 668270-12-0)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.

commoda:

FAQ:

Applicatio:

8-Bromo-7-(2-butyn-1-yl)-3-methylxanthinum (CAS: 666816-98-4) medium est pro Linagliptin (CAS: 668270-12-0).Linagliptin oralis est, inhibitor valde selectivus de dipeptidylo peptidasi-4 et est primum agens classis suae ut per viam nonrenam praevalens eliminandam.Linagliptin indicatur semel in usu quotidiano ad curationem adultorum cum specie 2 diabete melliti.Linagliptin ab US FDA mense Maio MMXI probatus est ad tractationem Type 2 diabetae una cum victu et exercitatione.